Table 2.

Therapeutic strategies directed against MDSCs

	Name/product	Mechanism of action	Specie	References
Conventional therapeutics	Gemcitabine	MDSCs depletion	Human Mouse	Eriksson et al. (2016); Suzuki et al. (2005)
	5-Fluoroascil	MDSC depletion by activation of caspases 3 and 7	Mouse	Vincent et al. (2010)
	Sunitinib AZD9150	STAT1 and STAT3 inhibition	Human	Ko et al. (2009); Li et al. (2021); Shastri et al. (2018)
	Decitabine	MDSC depletion	Mouse	Seong et al. (2016); Wagner Grau (2011)
	Tadalafil	MDSC reduction in periphery and tumor	Human	Califano et al. (2015)
	Anti-CXCR2 or Anti-CCR2	Decreased of MDSCs infiltration	Mouse	Sun et al. (2019)
	Bevacizumab	Inhibits VEGF, reduces MDSC infiltration into the tumor	Human	Koinis et al. (2016)
	L-NAME ASP9853 INCB001158	Decrease of immunosuppressive molecules	Human Mouse	Granados-Principal et al. (2015); Kuriakose (2016); Luke et al. (2016)
	Paclitaxel	Differentiation of MDSCs to DCs via TLR-4	Mouse	Michels et al. (2012); Sevko et al. (2013)
	ATRA	MDSCs maturation	Mouse	Al-Qassab et al. (2018); Molina-Jijon et al. (2015)
Natural products	Beta-glucans: Curdlan	MDSC modulation by activation of dectin-1 and NF-κB	Mouse	McIntosh et al. (2005); Tian et al. (2013)
	Fruiting bodies of Ganoderma lucidum	MDSCs reduction in spleen and tumor Decrease of immunosuppressive molecules	Mouse	Wang et al. (2020)
	Epigallocatechin-3-gallate (EGCG)	Reduction of intratumoral MDSCs infiltration and differentiation of PMN-MDSCs to mature PMN	Human Mouse	Croce et al. (2010); Santilli et al. (2013); Tachibana (2011)
	Curcumin	Decreased infiltration and expansion of intratumoral MDSCs Decrease of immunosuppressive molecules and IL-6	Mouse	Liu et al 2016; Lu et al. 2016
	Resveratrol	Differentiation of MDSCs to DCs	Mouse	Singh et al. 2007; Zhao et al. 2018
	OLE	ROS/RNS decrease in MDSCs	Mouse	Ashourpour et al. 2016
	P2Et	Decreased of MDSC in spleen and tumor	Mouse	Lasso et al. 2018, 2022

L-NAME nitro-L-arginine methyl ester, OLE olive leaves extract